NCT06387186View on ClinicalTrials.gov

Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Refractory EpilepsyDrug Resistant Epilepsy
Interventions
DRUG

Leucine-Enriched Essential Amino Acid powder

Leucine-Enriched Essential Amino Acid Powder will be orally/enterally administered by mixing in water or ketogenic formula.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Ajinomoto USA, INC.

INDUSTRY

collaborator

Ajinomoto Co., Inc.

INDUSTRY

lead

Elizabeth Anne Thiele

OTHER